Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer

Bella Kaufman1, Steven Stein2, Michelle A Casey2, Beth O Newstat21Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 2GlaxoSmithKline, Collegeville, PA, USAAbstract: Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bella Kaufman, Steven Stein, Michelle A Casey, Beth O Newstat
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/dd9c4211d0fd47b0951299d9a0982d43
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dd9c4211d0fd47b0951299d9a0982d43
record_format	dspace
spelling	oai:doaj.org-article:dd9c4211d0fd47b0951299d9a0982d432021-12-02T05:03:20ZLapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer1177-54751177-5491https://doaj.org/article/dd9c4211d0fd47b0951299d9a0982d432008-03-01T00:00:00Zhttp://www.dovepress.com/lapatinib-in-combination-with-capecitabine-in-the-management-of-erbb2--a54https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Bella Kaufman1, Steven Stein2, Michelle A Casey2, Beth O Newstat21Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 2GlaxoSmithKline, Collegeville, PA, USAAbstract: Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced breast cancer previously treated with an anthracycline, a taxane, and trastuzumab were reported early based on superiority of the combination in prolonging time to tumor progression (TTP). An updated analysis in 399 women supports the earlier findings. In this updated analysis, TTP (hazard ratio [HR] 0.57) favored lapatinib plus capecitabine. Survival trended in favor of the combination. The incidence of cardiac events was numerically higher in the combination arm (5 cases in the combination arm, 2 cases in the monotherapy arm).Keywords: lapatinib, capecitabine, breast cancer, HER2 Bella KaufmanSteven SteinMichelle A CaseyBeth O NewstatDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 1, Pp 61-65 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Bella Kaufman Steven Stein Michelle A Casey Beth O Newstat Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
description	Bella Kaufman1, Steven Stein2, Michelle A Casey2, Beth O Newstat21Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 2GlaxoSmithKline, Collegeville, PA, USAAbstract: Lapatinib is an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2). Results of a phase III study comparing lapatinib plus capecitabine with capecitabine alone in women with ErbB2-overexpressing advanced breast cancer previously treated with an anthracycline, a taxane, and trastuzumab were reported early based on superiority of the combination in prolonging time to tumor progression (TTP). An updated analysis in 399 women supports the earlier findings. In this updated analysis, TTP (hazard ratio [HR] 0.57) favored lapatinib plus capecitabine. Survival trended in favor of the combination. The incidence of cardiac events was numerically higher in the combination arm (5 cases in the combination arm, 2 cases in the monotherapy arm).Keywords: lapatinib, capecitabine, breast cancer, HER2
format	article
author	Bella Kaufman Steven Stein Michelle A Casey Beth O Newstat
author_facet	Bella Kaufman Steven Stein Michelle A Casey Beth O Newstat
author_sort	Bella Kaufman
title	Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
title_short	Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
title_full	Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
title_fullStr	Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
title_full_unstemmed	Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
title_sort	lapatinib in combination with capecitabine in the management of erbb2-positive (her2-positive) advanced breast cancer
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/dd9c4211d0fd47b0951299d9a0982d43
work_keys_str_mv	AT bellakaufman lapatinibincombinationwithcapecitabineinthemanagementoferbb2positiveher2positiveadvancedbreastcancer AT stevenstein lapatinibincombinationwithcapecitabineinthemanagementoferbb2positiveher2positiveadvancedbreastcancer AT michelleacasey lapatinibincombinationwithcapecitabineinthemanagementoferbb2positiveher2positiveadvancedbreastcancer AT bethonewstat lapatinibincombinationwithcapecitabineinthemanagementoferbb2positiveher2positiveadvancedbreastcancer
_version_	1718400742356680704

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer

Ejemplares similares